Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
A retrospective analysis of the efficacy between dasatinib and nilotinib for chronic myeloid leukemia
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Poster
- By: WU, Chia-Hsuan (Chi-Mei Medical Center, Pharmacy, Tainan, China Taiwan)
- Co-author(s): Yu-Jou Lin Department of Pharmacy, Chi-Mei Medical Center, Tainan City, Taiwan, Province of China
BackgroundChronic myeloid leukemia(CML) is a myeloproliferative disorder. Treatment decisions for CML include hematopoietic cell transplantation, tyrosine kinase inhibitors(TKIs) and other agents. TKIs including imatinib, dasatinib and nilotinib are often the first line therapy for newly diagnosed patients with CML.
PurposeImatinib was the first.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019